netupitant + palonosetron hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
netupitant + palonosetron hydrochloride: clinical details
Prescribing considerations
- Confirm that the indication is prevention of chemotherapy-induced nausea and vomiting in an adult.
- Review CYP3A4, serotonergic and QT-prolonging medicines before administration.
- Use caution in severe hepatic impairment and in people older than 75 years because experience is limited.
- Avoid use in end-stage renal disease requiring haemodialysis because safety and pharmacokinetic data are unavailable.
- Assess patients with constipation or possible subacute intestinal obstruction carefully.
- Correct hypokalaemia or hypomagnesaemia before administration when QT risk is relevant.
Contraindications and cautions
- Pregnancy
- Hypersensitivity to netupitant, palonosetron or an excipient
- The capsule should not be used in rare hereditary fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
Monitoring
- Clinical control of acute and delayed nausea and vomiting
- Constipation and symptoms of bowel obstruction
- Serotonin-syndrome symptoms when serotonergic medicines are used
- Toxicity from CYP3A4-substrate chemotherapy or narrow-therapeutic-index medicines
- ECG or electrolytes when individual QT-prolongation risk warrants assessment
- Allergic reactions in patients with peanut or soya hypersensitivity
Clinical pharmacology
Netupitant selectively antagonises NK1 receptors and is principally metabolised through CYP3A4. Palonosetron is a high-affinity 5-HT3-receptor antagonist eliminated through renal and multiple metabolic pathways. The complementary mechanisms target substance P-mediated delayed emesis and serotonin-mediated acute emesis.
Formulation and product differences
- The selected product is an oral opaque gelatin hard capsule containing netupitant tablets and a palonosetron soft capsule.
- It contains sorbitol and sucrose, is essentially sodium-free and may contain traces of soya-derived lecithin.
- The capsule must be swallowed whole and can be taken with or without food.
netupitant + palonosetron hydrochloride preparations and strengths
Capsule
Route: Oral
Strengths: 300 mg + 0.5 mg
netupitant + palonosetron hydrochloride interactions
Netupitant is a CYP3A4 substrate and moderate inhibitor, so clinically important interactions are possible.
Dexamethasone
Netupitant increases dexamethasone exposure, so the oncology prescriber must adjust the antiemetic plan accordingly.
Strong CYP3A4 inducers, such as rifampicin
They can lower netupitant exposure and reduce anti-sickness efficacy; concomitant use should be avoided.
Strong CYP3A4 inhibitors, such as ketoconazole
They can increase netupitant exposure, requiring clinical caution.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.